The protein amyloid beta is believed to be the major cause of Alzheimer’s disease. Substances that reduce the production of amyloid beta, such as BACE inhibitors, are therefore promising candidates for new drug treatments. Scientists have recently demonstrated that one such BACE inhibitor reduces the amount of amyloid beta in the brain. By doing so, it can restore the normal function of nerve cells and significantly improve memory performance.